ResearcherChina Pharmaceutical UniversityNo recent work listed

Yijun Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4920-152X; OpenAlex author ID A5100413918. Sources: OpenAlex.

Their work

Papers: 3 (first author 0, last author 2)
Trials: 0
Grants: 0
Labs led: 1
Collaborators: 4

Papers, trials and grants by year

2017: 1 paper · 2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 1 paper

Papers 3

The ufmylation modification of ribosomal protein L10 in the development of pancreatic adenocarcinoma. Last author DOI 10.1038/s41419-023-05877-y ↗
Ribosomal protein L10 in mitochondria serves as a regulator for ROS level in pancreatic cancer cells. Last author DOI 10.1016/j.redox.2018.08.016 ↗
Cooperative down-regulation of ribosomal protein L10 and NF-κB signaling pathway is responsible for the anti-proliferative effects by DMAPT in pancreatic cance… Co-author DOI 10.18632/oncotarget.16557 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Nan Liu · 2 shared papers, 2017–2018 · strength 0.21
- Paper Ribosomal protein L10 in mitochondria serves as a regulator for ROS level in pancreatic cancer cells. DOI 10.1016/j.redox.2018.08.016 ↗
- Paper Cooperative down-regulation of ribosomal protein L10 and NF-κB signaling pathway is responsible for the anti-proliferat… DOI 10.18632/oncotarget.16557 ↗
Kun Wang · 1 shared paper, 2023 · strength 0.20
- Paper The ufmylation modification of ribosomal protein L10 in the development of pancreatic adenocarcinoma. DOI 10.1038/s41419-023-05877-y ↗
Jun Yang · 1 shared paper, 2018 · strength 0.12
- Paper Ribosomal protein L10 in mitochondria serves as a regulator for ROS level in pancreatic cancer cells. DOI 10.1016/j.redox.2018.08.016 ↗
Shi Chen · 1 shared paper, 2017 · strength 0.09
- Paper Cooperative down-regulation of ribosomal protein L10 and NF-κB signaling pathway is responsible for the anti-proliferat… DOI 10.18632/oncotarget.16557 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.